Announcement PDF Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com ASX ANNOUNCEMENT 4 February 2026 Investor Webinar Melbourne, Australia; 4 February 2026: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, reminds shareholders that CEO and Managing Director, Dr Kilian Kelly, will host an investor webinar today, Wednesday 4 February 2026 at 11:30am AEDT. Attendees are required to register in advance for the webinar using the following link: https://us02web.zoom.us/webinar/register/WN_3WketK2XQxSSYd1Elef27g Upon registration, attendees will receive details to access the webinar. A copy of the presentation to be delivered during the webinar is attached to this announcement. After the webinar is complete, a recording will be available on the Company’s InvestorHub portal. This portal enables shareholders, stakeholders, prospective investors and partners to learn more about the Company'sactivitiesand key projects. The Company regularly uploads new content to the hub, including videos, key project news and updates. Shareholders and interested parties can join InvestorHub via the “sign up” button on the Company’s website (www.cynata.com). -ENDS- Authorised for release by Dr Kilian Kelly, CEO & Managing Director CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods. Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Investor Webinar: Quarterly Update 4th February 2026 (ASX:CYP) Important Information Summaryinformation This Presentation contains summary informationabout Cynata Therapeutics Limited and its subsidiaries (CYP, or Cynata) which is current as at 3rd February 2026. This Presentationshould be read inconjunction with CYP’s other periodicand continuousdisclosure information lodgedwith theAustralian Securities Exchange (ASX),which are available at www.asx.com.au. Not an offer This Presentation is not a prospectus,product disclosure statement or other offering document under Australian law (and willnot be lodged with the ASIC) or any other law.This Presentation is for information purposes only andis not an invitationorofferof securities forsubscription,purchase or sale inanyjurisdiction.The release,publication or distributionof this Presentation (including an electroniccopy) outsideAustralia may be restricted by law. If you come into possessionof this Presentation,you should observe such restrictions.Any non-compliance with these restrictions may contravene applicable securities laws. Not investmentadvice ThisPresentation doesnot constituteinvestment or financial product advice (nor tax,accounting or legaladvice) or any recommendationbyCYP orits advisers to acquire CYPsecurities. This Presentationhas beenprepared without taking account of any person’s individual investment objectives, financial situation or particular needs. Beforemaking an investment decision, prospectiveinvestorsshouldconsider the appropriatenessof the information having regard to theirowninvestment objectives,financialsituationandneeds and seek legal, accounting and taxation advice appropriate to their jurisdiction.CYPis not licensed to provide financialproduct advicein respect of CYPsecurities. Investment risk andpast performance An investment in CYPsecuritiesis subject to known and unknownrisks,someof which are beyond the controlof CYP and its directors.CYPdoes not guaranteeanyparticular rateof returnor performanceof CYP. Past performancecannot be relied upon as an indicatorof (andprovidesno guidance as to) future CYP performanceincluding future share price performance. Financial data All financial information inthis Presentation isin Australiancurrency (A$) unlessotherwise stated.This Presentation contains historical financial information based onfinancialinformationthat has been disclosed to theASX. Any discrepancies betweentotals and sums of components in tables and figures inthis Presentation aredue torounding. Forward-looking statements This Presentation contains certain ‘forward-looking statements’, whichcan generallybeidentified by the useof forward looking words such as ‘expect’, ‘anticipate’,‘likely’, ‘intend’, ‘should’, ‘could’,‘may’,‘predict’,‘plan’, ‘propose’,‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’,‘guidance’,‘potential’andothersimilarexpressions.The forward looking statements contained inthis Presentation are not guaranteesor predictions of future performanceand involve known and unknown risks and uncertainties and other factors, many ofwhich are beyond the controlof CYP, its directors and management, and may involve significant elements of subjectivejudgment and assumptionsas to future events which may ormay not becorrect.There can be no assurance that actual outcomes will not differmaterially from these forward looking statements. A number ofimportant factorscould cause actualresults or performance to differ materially from the forward looking statements. No representationorwarranty, expressorimplied, is made as to the accuracy,likelihood of achievement orreasonablenessof any forecasts,prospects, returns or statements inrelation to futurematterscontained in this Presentation. The forward looking statements arebased on information availableto CYPas at thedateof this Presentation.Except asrequired bylawor regulation(including theASX Listing Rules), CYP and its directors,officers, employees,advisers, agents and intermediariesundertake no obligation to provideany additionalor updated informationwhether as aresult of new information,futureevents or results or otherwise. Youare strongly cautioned not to place undue reliance on forward-looking statements. IndustryandMarketdata Certainmarket and industry dataused inconnectionwiththis Presentation may havebeen obtained from research, surveys or studiesconducted by third parties,including industryorgeneral publications.NeitherCYPnorits representativeshaveindependentlyverified any suchmarket orindustry data provided by thirdparties orindustry or general publications. Disclaimer To themaximum extent permitted by law, CYPand its advisers,affiliates,related bodies corporate,directors, officers, partners, employees and agents (RelatedPersons) excludeand disclaim allliability, including without limitation for negligence, forany expenses, losses,damages orcosts arising fromthis Presentation orrelianceonanything contained inor omitted from it. To themaximum extent permitted by law, CYPand its Related Persons make no representation or warranty, express or implied, as to thecurrency, accuracy,reliabilityor completenessof informationin this Presentation and disclaim any obligation orundertaking toreleaseanyupdate orrevisionto the information inthis Presentation to reflect any change in expectations orassumptions. Statements madein this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice. cynata.com 2 Clinical Countdown We are approaching a moment of rare opportunity for an ASX biotech 3 cynata.com Entering the most important chapter in Cynata’s history Two major clinical trial readouts this financial year Results could transform Cynata’s commercial trajectory and valuation Trials designed to validate the real-word impact of our Cymerus platform Strong safety and human efficacy already demonstrated in prior trials Entering this phase with validated clinical signals and compelling risk vs reward profile Cynata’s MSCs In Storage Major Clinical Milestones Achieved 4 cynata.com 1 - As of 31 December 2026 2 – ASX Announcement ‘Cynata Completes $1.2m At-The-Market Raise’ 23rd Jan 2026 Phase 3 osteoarthritis patient visits complete - results expected in Q2 CY26 Phase 2 aGvHD enrolment completed - results expected in Q2 CY26 Kidney transplant program advanced, first cohort completed following positive DSMB review IP portfolio strengthened, with multiple patent allowances granted in the US & Europe Active engagement with global regulators to progress approval pathways $2.6m at quarter end1, with a further A$1.2 million raised via ATM facility2 1. Global Graft versus Host Disease Market 2019-2029 (Reflectsforecast marketin 2026) 2. Zion Market Research, 2019 (represents global treatment market in 2025) 3. Persistence Market Research 2018 research report: “Osteoarthritis Treatment Market: Global Industry Analysis (2012 -2016) and Forecast (2017-2025) (Reflect OA market by 2025); 4. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019 * Timing of events is approximate, based on the Company’s information as at the date of this presentation, and subject to change. CY = calendar year. 5 cynata.com Tightly focused clinical pipeline Advancing four clinical programs to address critical treatment gaps Company- (and industry-) defining data readouts this financial year Manufacturing process established and ready to scale Positioned well for global licensing and joint venture deals Phase 1 Market Size Phase 2 Phase 3 Next Catalyst* US$11.6bn3 Osteoarthritis CYP-004 Acute Graft vs Host Disease Diabetic Foot Ulcers CYP-001 CYP-006TK Kidney Transplantation CYP-001 Results: Q2 CY 2026 Results: Q2 CY 2026 Results Released: Dec 2024 Cohort 1 Results: Q4 CY 2025 US$600m1 US$9.6bn2 US$5.9bn4 Complete Ongoing Cynata Is At An Inflection Point Patient Visits Complete Enrolment Complete aGvHD: Phase 2 Trial 6 cynata.com Results Expected Q2 CY2026 Fully recruited Phase 2 trial (65 patients) across AU, US & Europe High-risk, newly diagnosed aGvHD patients CYP-001 + steroids vs steroids alone Primary endpoint: Overall Response Rate (Day 28) Data expected Q2 CY26 (100-day assessment) Strong Phase 1 efficacy and safety profile Osteoarthritis: Phase 3 Trial 7 cynata.com Results Expected Q2 CY26 Phase 3 SCUlpTOR trial completed (2-year follow-up) 321 patients with knee osteoarthritis CYP-004 vs placebo (intra-articular injection) Primary endpoints: pain reduction & cartilage thickness Data expected Q2 2026 Positive results may support Australian approval (per-TGA advice) Kidney Transplantation: Phase 1/2 Trial 8 cynata.com Phase 1/2 NEREID trial ongoing (investigator-led) Positive DSMB review of first patient cohort No rejection events or safety concerns observed CYP-001 targeting reduced immunosuppressant reliance Cohort 2 approved to commence 1. Trial being conducted and funded by Leiden University Medical Center 2. DSMB =Data andSafety MonitoringBoard At-the-Market (ATM) Facility 9 cynata.com Purpose The ATM is a flexible funding facility, established in August 2025 It provides Cynata with up to $7.5m of standby equity capital over five years (up to July 2031) Cynata has full discretion over: • If and when the ATM is used • How much capital is raised • The minimum issue price There is no obligation to use the ATM and it can be paused or terminated at any time Recent $1.2m Raise Cynata raised A$1.2 million (net of costs) through its ATM facility The capital was raised to support near-term working capital requirements The ATM facility remains available as a standby funding option, which the Company may or may not choose to utilise in the future, subject to capital needs and market conditions 10 cynata.com Entering a data-driven phase, with multiple advanced trials now complete and key clinical readouts expected in Q2 CY26 Phase 3 osteoarthritis and Phase 2 aGvHD results expected to inform next-stage development and regulatory strategy Early engagement continues with potential partners, to explore potential commercial and development opportunities post data Active regulatory dialogue in Australia and internationally to clarify approval pathways and accelerate future timelines Pipeline expansion opportunities progressing Focused capital discipline, ensuring flexibility to execute on post-data opportunities and strategic outcomes Outlook But I must explain to you how this Service Three But I must explain to you how this Service One But I must explain to you how this Service Five Solves the MSC manufacturing bottleneck with single- donor scalability First mover with no direct peers - only clinical grade iPSC MSC platform at scale Lead asset backed by FDA Orphan Drug designation and solid IP protection Landmark Phase 2 & 3 readouts expected this financial year Fully funded through major clinical milestones Trades at a discount to biotech peers despite sector leadership Investment The Case Why Cynata? Why Now? 11 cynata.com Thank You. Cynata Therapeutics Limited Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia +61 (03) 7067 6940 investors@cynata.com www.cynata.com